Report : Asia Pacific Diltiazem Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Capsules, Injection, and Tablets) and Application (Angina, Hypertension, and Others)
The capsules segment by product type is estimated to lead the market growth during the forecast period.
According to a new market research study of “Asia Pacific Diltiazem Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product Type, Application, and Country.” The Asia Pacific diltiazem market is expected to reach US$ 160.34 million by 2028 from US$ 67.84 million in 2021; it is estimated to grow at a CAGR of 13.1% from 2021 to 2028. The report highlights trends prevailing in the Asia Pacific diltiazem market and the factors driving market along with those that act as hindrances.
The prevalence of cardiovascular conditions is rising across the world, especially in developing nations. In these nations, the modernized facilities reduced the physical activities of people. Also, the stress level among people is growing. The incidence of CVDs is rising in developing countries, owing to the shift in lifestyle and the other health conditions caused due to the adoption of modernized facilities, which is propelling the demand for Diltiazem. The developing nations are significantly developing their healthcare facilities and services and are heading toward technological advancements. For instance, the structural heart is at the initial stage of development in the regions such as Asia Pacific. In March 2021, Glenmark Pharma gained the final USFDA nod on diltiazem hydrochloride capsules. Glenmark Pharmaceuticals has been granted a competitive generic therapy (CGT) designation for Diltiazem Hydrochloride Extended?Release Capsules USP, 60 mg, 90 mg, and 120 mg. With the approval, the company has become the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing. Also, Glenmark is expanding its footprint in Switzerland and other developing countries. Thus, the opportunities for the market players to enter the market with cost-effective products are higher. Therefore, the factors mentioned above would create lucrative opportunities for the growth of the diltiazem market during the forecast period. Also, the diltiazem market is characterized by various small and big companies across Asia Pacific. The market players adopt strategies such as new product launches, regional expansions, and product approvals to increase their market share. The players are investing in R&D to develop advanced technologies and gain significant revenue share. Thus, recent developments are expected to act as a future trend in the diltiazem market.
COVID-19 pandemic has broadly affected economies in the Asia Pacific region. The pandemic has affected three main aspects of the global economy – production, supply chain, and firms and financial markets. The supply chain disruptions and the massive demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. Recently, patients with both hypertension and obesity have been increasing in Japan at exceptionally high risk of COVID-19, and thus, they need careful observation and intensive treatment. However, it is essential to note that the therapeutic mechanism of calcium channel blockers against COVID-19 still awaits further investigation and randomized controlled clinical trials. This scenario is positively impacting the diltiazem market in Asia Pacific.
The Asia Pacific diltiazem market, based on product is segmented into capsules, injection, and tablets. The Asia Pacific diltiazem market based on the application was segmented into angina, hypertension, and others. Geographically, the Asia Pacific diltiazem market can be sub-segmented into India, Japan, China, South Korea, Australia, Rest of Asia Pacific.
Bausch Health Companies Inc., Teva Pharmaceutical Industries Ltd, MYLAN N.V., Pfizer Inc., Sandoz (Novartis AG), Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals PLC, Zydus Cadila, and Glenmark are among the leading companies operating in the Asia Pacific diltiazem market.